Press-center

July 22nd, 2024

ECZACIBAŞI-MONROL SHAREHOLDERS SIGNED A SHARE TRANSFER AGREEMENT WITH CURIUM

A share purchase agreement was signed on 05 April 2024 to transfer the majority of our company's shares to Curium International Trading B.V.

11
 September
 2023

Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity

ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.

18
 November
 2022

Monrol and FutureChem Announced a Clinical Supply Partnership

ISTANBUL & SEOUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) is delighted to announce that it has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply..

28
 September
 2022

Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany

ISTANBUL--(BUSINESS WIRE)--Following an ongoing assessment of its entire operation, Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.

09
 June
 2022

Monrol and ImaginAb Announce Supply, Manufacturing and Distribution Partnership

Inglewood, California and Istanbul, Turkey – June 9, 2022 - ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radioligand therapy (RLT), is delighted to announce that...

10
 May
 2022

Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial

ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product..

28
 January
 2022

Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium

ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added177Lu (n.c.a.177Lu)...

24
 November
 2021

MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.

WEST CHESTER, Pa. & ISTANBUL--(BUSINESS WIRE)--Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative...

22
 October
 2020

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey

MELBOURNE, Australia and ISTANBUL, Turkey, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) and Eczacıbaşı-Monrol Nuclear Products Co. (‘Eczacıbaşı Monrol’) are pleased to announce that the first...

13
 June
 2019

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products...